Literature DB >> 15774920

Macular function and morphology after peeling of idiopathic epiretinal membrane with and without the assistance of indocyanine green.

J Hillenkamp1, P Saikia, F Gora, H G Sachs, C P Lohmann, J Roider, W Bäumler, V-P Gabel.   

Abstract

AIM: To investigate macular function and morphology after surgical removal of idiopathic epiretinal membrane (IEM) with and without assistance of indocyanine green (ICG).
METHODS: A retrospective study as a consecutive case series, of 39 patients with IEM. 39 patients, 23 female, 16 male, mean age 67 years, underwent standard three port pars plana vitrectomy with removal of epiretinal membrane. Two groups of patients were consecutively operated: in 20 patients ICG 0.1% in glucose 5% was used to stain the epiretinal membrane. 19 patients underwent the identical procedure but without use of ICG. Postoperative follow up was 1-92 months (mean 15.5 months). Functional outcome was assessed with subjective improvement, best corrected visual acuity (BCVA), Amsler grid test, 10 degrees and 30 degrees automated perimetry (Heidelberg visual field analyser) (HFA), and Goldmann kinetic perimetry. Macular morphology was assessed with stereoscopic biomicroscopy and optical coherence tomography (OCT). The main outcome measures were macular function as determined by BCVA, presence of visual field defects, and metamorphopsia as determined by Amsler grid test, macular morphology as determined by slit lamp biomicroscopy, and OCT.
RESULTS: BCVA improved in 28 patients, remained unchanged in eight patients, and decreased in three patients. Improvement of BCVA was statistically significant in both groups (p = 0.003). Mean BCVA in patients operated with ICG improved from 0.33 preoperatively to 0.53 postoperatively. Mean BCVA in patients operated without ICG improved from 0.32 preoperatively to 0.54 postoperatively. Reduction of macular oedema as measured by OCT was statistically significant in both groups (p<0.01). There was no statistically significant difference in postoperative BCVA, macular oedema as measured by OCT, postoperative Amsler grid test, and subjective improvement between the two groups. The incidence of residual or recurrent epiretinal membrane was greater in the group operated without ICG (p = 0.014). Visual field defects were detected in one patient operated with ICG and in three patients operated without ICG.
CONCLUSIONS: Removal of epiretinal tissue with or without assistance of ICG improved visual function and reduced macular oedema in most patients. Adverse effects clearly attributable to the use of ICG were not observed but further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774920      PMCID: PMC1772583          DOI: 10.1136/bjo.2004.051250

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  39 in total

1.  Characterization of epiretinal membranes using optical coherence tomography.

Authors:  J R Wilkins; C A Puliafito; M R Hee; J S Duker; E Reichel; J G Coker; J S Schuman; E A Swanson; J G Fujimoto
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

2.  Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia.

Authors:  P Mitchell; W Smith; T Chey; J J Wang; A Chang
Journal:  Ophthalmology       Date:  1997-06       Impact factor: 12.079

3.  Epiretinal and vitreous membranes. Comparative study of 56 cases.

Authors:  A Kampik; K R Kenyon; R G Michels; W R Green; Z C de la Cruz
Journal:  Arch Ophthalmol       Date:  1981-08

4.  Ultrastructural features of progressive idiopathic epiretinal membrane removed by vitreous surgery.

Authors:  A Kampik; W R Green; R G Michels; P K Nase
Journal:  Am J Ophthalmol       Date:  1980-12       Impact factor: 5.258

5.  Visual field loss following vitrectomy for stage 2 and 3 macular holes.

Authors:  E Ezra; G B Arden; P Riordan-Eva; G W Aylward; Z J Gregor
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

6.  Classification of aphakic cystoid macular edema with focal macular electroretinograms.

Authors:  Y Miyake; K Miyake; N Shiroyama
Journal:  Am J Ophthalmol       Date:  1993-11-15       Impact factor: 5.258

7.  Anatomic and visual outcomes after indocyanine green-assisted peeling of the retinal internal limiting membrane in idiopathic macular hole surgery.

Authors:  Fumitaka Ando; Kumiko Sasano; Norio Ohba; Hiroshi Hirose; Osamu Yasui
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

8.  Effects of indocyanine green on the retina and retinal pigment epithelium in a porcine model of retinal hole.

Authors:  Marcin P Czajka; Brooks W McCuen; Thomas J Cummings; Hoang Nguyen; Sandra Stinnett; Fulton Wong
Journal:  Retina       Date:  2004-04       Impact factor: 4.256

9.  Histology of the vitreoretinal interface after staining of the internal limiting membrane using glucose 5% diluted indocyanine and infracyanine green.

Authors:  Christos Haritoglou; Arnd Gandorfer; Carolin A Gass; Anselm Kampik
Journal:  Am J Ophthalmol       Date:  2004-02       Impact factor: 5.258

10.  Visual field loss following vitreous surgery.

Authors:  J B Kerrison; J A Haller; M Elman; N R Miller
Journal:  Arch Ophthalmol       Date:  1996-05
View more
  18 in total

1.  Outcomes of idiopathic macular epiretinal membrane removal with and without internal limiting membrane peeling: a comparative study.

Authors:  Ji Woong Lee; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2010-04-18       Impact factor: 2.447

2.  Expression of glutamine synthetase and cell proliferation in human idiopathic epiretinal membrane.

Authors:  S Kase; W Saito; M Yokoi; K Yoshida; N Furudate; M Muramatsu; A Saito; M Kase; S Ohno
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

Review 3.  [Statement of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on the development, diagnostics and treatment of epiretinal gliosis : Status October 2020].

Authors: 
Journal:  Ophthalmologe       Date:  2021-02       Impact factor: 1.059

4.  Superficial foveal avascular zone area changes before and after idiopathic epiretinal membrane surgery.

Authors:  Yo Sep Yoon; Je Moon Woo; Jong Eun Woo; Jung Kee Min
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

5.  Role of ganglion cell complex in visual recovery following surgical internal limiting membrane peeling.

Authors:  Luisa Pierro; Lorenzo Iuliano; Marco Gagliardi; Marco Codenotti; Alessandro Ambrosi; Francesco Bandello
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-23       Impact factor: 3.117

6.  Reflectivity and thickness analysis of epiretinal membranes using spectral-domain optical coherence tomography.

Authors:  Ajay E Kuriyan; Delia Cabrera DeBuc; William E Smiddy
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

7.  [Staining techniques in macular surgery].

Authors:  C Haritoglou; A Kampik
Journal:  Ophthalmologe       Date:  2006-11       Impact factor: 1.059

8.  20 g PPV with indocyanine green-assisted ILM peeling versus 23 g PPV with brilliant blue G-assisted ILM peeling for epiretinal membrane.

Authors:  Kleanthis Manousaridis; Silvia Peter; Stefan Mennel
Journal:  Int Ophthalmol       Date:  2015-10-23       Impact factor: 2.031

9.  Indocyanine green-assisted epiretinal membrane peeling evaluated by optical coherence tomography and multifocal electroretinography.

Authors:  Chryssanthi N Koutsandrea; Michael N Apostolopoulos; Dimitrios A Alonistiotis; Marilita M Moschos; Efstratia Georgiadou; Theodora E Kyriaki; Gerasimos T Georgopoulos; Michael N Moschos
Journal:  Clin Ophthalmol       Date:  2007-12

10.  Comparison of macular function and visual fields after membrane blue or infracyanine green staining in vitreoretinal surgery.

Authors:  Katharina E Schmid-Kubista; Peggy D Lamar; Alexandra Schenk; Ulrike Stolba; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-13       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.